Evidence map›Paper›PMID 34748541›Full record

ArticlePLoS computational biology2021

Computational redesign of a fluorogen activating protein with Rosetta.

Nina G Bozhanova, Joel M Harp, Brian J Bender, Alexey S Gavrikov, Dmitry A Gorbachev, Mikhail S Baranov, Christina B Mercado, Xuan Zhang, Konstantin A Lukyanov, Alexander S Mishin and 1 more

Open access · goldAbstract read
In one paragraph

Article in PLoS computational biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Nina G BozhanovaDepartment of Chemistry and Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, United States of America.ORCID 0000-0002-2164-5698
Joel M HarpDepartment of Biochemistry, School of Medicine, Vanderbilt University, Nashville, Tennessee, United States of America.ORCID 0000-0002-9116-5606
Brian J BenderDepartment of Pharmacology and Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, United States of America.ORCID 0000-0001-9251-9480
Alexey S GavrikovInstitute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.ORCID 0000-0002-5696-594X
Dmitry A GorbachevInstitute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.ORCID 0000-0001-6124-2511
Mikhail S BaranovInstitute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
Christina B MercadoDepartment of Chemistry and Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, United States of America.ORCID 0000-0001-9962-817X
Xuan ZhangDepartment of Chemistry and Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, United States of America.ORCID 0000-0001-5163-0668
Konstantin A LukyanovInstitute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.ORCID 0000-0001-9845-2088
Alexander S MishinInstitute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.ORCID 0000-0002-4935-7030
Jens MeilerDepartment of Chemistry and Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, United States of America.ORCID 0000-0001-8945-193X
Vanderbilt University · USInstitute of Bioorganic Chemistry · RUPirogov Russian National Research Medical University · RU

Funding

Computational Design of Protein-Ligand Interfaces - a Therapeutic StrategyR01GM099842 · NIGMS · VANDERBILT UNIVERSITY · PI MEILER, JENS · 2012 to 2015
$1.3M
High-Performance Computer Cluster for Biomedical ResearchS10OD023680 · OD · VANDERBILT UNIVERSITY · PI MEILER, JENS · 2017 to 2017
$587k
Hybrid Methods for Prediction and Design of Novel Human Influenza AntibodiesR56AI110750 · NIAID · VANDERBILT UNIVERSITY · PI CROWE, JAMES E, MEILER, JENS · 2014 to 2014
$433k
NIAID NIH HHS R56 AI110750NIGMS NIH HHS R01 GM099842NIH HHS S10 OD023680
6 · The paper itself

Abstract

The use of unnatural fluorogenic molecules widely expands the pallet of available genetically encoded fluorescent imaging tools through the design of fluorogen activating proteins (FAPs). While there is already a handful of such probes available, each of them went through laborious cycles of in vitro screening and selection. Computational modeling approaches are evolving incredibly fast right now and are demonstrating great results in many applications, including de novo protein design. It suggests that the easier task of fine-tuning the fluorogen-binding properties of an already functional protein in silico should be readily achievable. To test this hypothesis, we used Rosetta for computational ligand docking followed by protein binding pocket redesign to further improve the previously described FAP DiB1 that is capable of binding to a BODIPY-like dye M739. Despite an inaccurate initial docking of the chromophore, the incorporated mutations nevertheless improved multiple photophysical parameters as well as the overall performance of the tag. The designed protein, DiB-RM, shows higher brightness, localization precision, and apparent photostability in protein-PAINT super-resolution imaging compared to its parental variant DiB1. Moreover, DiB-RM can be cleaved to obtain an efficient split system with enhanced performance compared to a parental DiB-split system. The possible reasons for the inaccurate ligand binding pose prediction and its consequence on the outcome of the design experiment are further discussed.

Indexed as

Amino Acid SequenceBoron CompoundsComputational BiologyCrystallography, X-RayDrug DesignFluorescenceFluorescent DyesHEK293 CellsHumansLuminescent ProteinsMicroscopy, FluorescenceModels, MolecularMolecular Docking SimulationProtein ConformationProtein EngineeringRecombinant Proteins4,4-difluoro-4-bora-3a,4a-diaza-s-indaceneBoron CompoundsFluorescent DyesLuminescent ProteinsRecombinant Proteins

Identifiers

PMID34748541
PMCPMC8601599
OpenAlexW3211722154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.